Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid...

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Tumor necrosis factor inhibitors (TNFi) are a class of biologic agents used to treat RA.
• Rheumatoid factor (RF) is an autoantibody often present in RA patients, but its impact on treatment response is debated.

Purpose of the Study:

• To compare the effectiveness of TNFi treatment in established RA patients based on rheumatoid factor (RF) status.
• To assess differences in functional status (HAQ-DI) and pain levels between RF-positive (RF+) and RF-negative (RF-) RA patients receiving TNFi therapy.

Main Methods:

• A cohort of established RA patients treated with TNFi was analyzed.
• Patients were categorized as RF-positive (RF+) or RF-negative (RF-).
• Changes in Health Assessment Questionnaire Disability Index (HAQ-DI) and pain scores (0-3 VAS) were measured one year after initiating TNFi treatment.

Main Results:

• While baseline characteristics were similar, RF+ patients (n=90) showed a significantly greater improvement in HAQ-DI compared to RF- patients (n=38) (-0.356 vs -0.126; P=0.04).
• Mean pain improvement was also significantly greater in RF+ patients (-0.725) versus RF- patients (-0.332; P=0.03).
• Disease duration was longer in RF+ patients, but TNFi treatment duration and continuation rates were similar between groups.

Conclusions:

• RF+ patients with established RA may exhibit a more favorable response to TNFi therapy concerning functional status and pain reduction.
• These findings suggest rheumatoid factor status could be a predictive marker for TNFi efficacy in RA.
• Further research with larger sample sizes and comprehensive data is warranted to confirm these observations.